Sequential therapy in the treatment of osteoporosis

Current Medical Research and Opinion

Volumn 27, Issue 6, 2011, Pages 1149-1155

  Boonen, Steven ^a   Milisen, Koen ^a   Gielen, Evelien ^a   Vanderschueren, Dirk ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Alendronate; Osteoporosis; Risedronate; Sequential therapy; Teriparatide

Indexed keywords

ALENDRONIC ACID; IBANDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; RECOMBINANT PARATHYROID HORMONE; RISEDRONIC ACID; ZOLEDRONIC ACID;

ADULT; BONE MASS; BONE STRENGTH; CLINICAL TRIAL (TOPIC); CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FRACTURE; HUMAN; LIBRARY; MALE; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RISK REDUCTION;

BONE DENSITY CONSERVATION AGENTS; DRUG COSTS; FRACTURES, BONE; HUMANS; OSTEOPOROSIS; RISK FACTORS;

EID: 79956083484     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.573545     Document Type: Review

References (60)

1. National Osteoporosis Foundation. Physician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation, 2008
2. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006; 17: 1726-33. (Pubitemid 44607392)
3. Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007;22:465-75 (Pubitemid 46797130)
4. Cole Z, Dennison E, Cooper C. Update on the treatment of post-menopausal osteoporosis. Br Med Bull 2008;86:129-43 (Pubitemid 351809634)
5. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998; 19:80-100 (Pubitemid 29122075)
6. McClung MR, San Martin J, Miller PD, et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 2005;165:1762-8 (Pubitemid 41138965)
7. Epstein S. Update of current therapeutic options for the treatment of postmenopausal osteoporosis. Clin Ther 2006;28:151-73
8. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41 (Pubitemid 26411651)
9. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000;85:4118-24 (Pubitemid 32055362)
10. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22 (Pubitemid 46698462)
11. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52 (Pubitemid 29483192)
12. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83-91 (Pubitemid 30099515)
13. RouxC, Seeman E, Eastell R, et al. Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 2004;20:433-9 (Pubitemid 38525150)
14. Harrington JT, Ste-Marie L-G, Brandi ML, et al. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 2004;74:129-35 (Pubitemid 38263854)
15. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333-40 (Pubitemid 32107641)
16. Chesnut III CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-9 (Pubitemid 41094364)
17. Felsenberg D, Czerwinski E, Stakkestad J, et al. Efficacy of monthly oral ibandronate is maintained over 5 years: the MOBILE LTE study. Osteoporosis Int 2009;20:S15
18. Black DM, Reid I, Cauley J, et al. The effect of 3 versus 6 years of zoledronic acid treatment in osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). Presented at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting. October 16, 2010
19. Sorensen OH, Crawford GM, Mulder H, et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 2003;32:120-6 (Pubitemid 36299139)
20. Mellstrom DD, Sorensen OH, Goemaere S, et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004;75:462-8 (Pubitemid 40174503)
21. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296:2927-38 (Pubitemid 46021497)
22. Schwartz AV, Bauer DC, Cummings SR, et al.; FLEX Research Group. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res 2010;25:976-82
23. Cosman F. Parathyroid hormone treatment for osteoporosis. Curr Opin Endocrinol Diabetes Obes 2008;15:495-501
24. FORTEO (teriparatide [rDNA origin]). Prescribing Information. Available at: http://pi.lilly.com/us/forteo-pi.pdf [Last accessed March 2011]
25. Preotact. Summary of product characteristics. Available at: http://www. medicines.org.uk/EMC/medicine/18249/SPC/Preotact/[Last accessed March 2011]
26. Neuprez A, Reginster JY. Bone-forming agents in the management of osteoporosis. Best Pract Res Clin Endocrinol Metab 2008;22:869-83
27. Graeff C, Timm W, Nickelsen TN, et al. Monitoring teriparatide associated changes in vertebral microstructure by high-resolution CT in vivo: Results from the EUROFORS study. J Bone Miner Res 2007;22:1426-33 (Pubitemid 351339687)
28. Zanchetta JR, Bogado C, Ferriti LJ, et al. Effects of LY333334 [recombinant parathyroid hormone (1-340)] on cortical bone strength indices as assessed by peripheral quantitative computed tomography. Bone 2001; 28(Suppl. 5):Abstract S86
29. Hyldstrup L, Jorgensen JT, Gaich G. Assessment of the effects of Iy333334 [recombinant parathyroid hormone (1-340)] on cortical bone using digital X-ray radiogrammetry. Bone 2001;28(Suppl. 5):Abstract S97
30. Body JJ, Gaich GA, Scheele WH. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002;87:4528-35 (Pubitemid 35247036)
31. Garnero P, Vergnaud P, Hoyle N. Evaluation of a fully automated serum assay for total N-terminal propeptides of type 1 collagen in postmenopausal osteoporosis. Clin Chem 2008;54:188-96 (Pubitemid 351182613)
32. Borah B, Dufresne TE, Ritman EL, et al. Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography. Bone 2006;39:345-52 (Pubitemid 43851366)
33. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41 (Pubitemid 32402100)
34. Ettinger B, San Martin J, Crans G, Pavo I. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004;19:745-51 (Pubitemid 41094385)
35. Keaveny TM, Donley DW, Hoffmann PF, et al. Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of OCT scans in women with osteoporosis. J Bone Miner Res 2007;22:149-57 (Pubitemid 46032608)
36. Jiang Y, Zhao JJ, Mitlak BH, et al. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003;18:1932-41 (Pubitemid 37377441)
37. Misof BM, Roschger P, Cosman F, et al. Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. J Clin Endocrinol Metab 2003;88:1150-6 (Pubitemid 36337769)
38. Dempster DW, Cosman F, Kurland ES, et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001; 16:1846-53 (Pubitemid 32911491)
39. Obermayer-Pietsch BM, Marin F, McCloskey EV, et al. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res 2008;23:1591-600
40. Mosekilde L, Mosekilde L. Sex differences in age-related changes in vertebral body size, density and biomechanical competence in normal individuals. Bone 1990;11:67-73 (Pubitemid 20226564)
41. Greenspan SL, Bone HG, Ettinger MP, et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 2007;146:326-39 (Pubitemid 351650593)
42. Black DM, Bouxsein ML, Palermo L, et al. Randomized trial of once-weekly parathyroid hormone (1-84) on bone mineral density and remodeling. J Clin Endocrinol Metab 2008;93:2166-72 (Pubitemid 351831531)
43. Bilezikian JP, Rubin MR. Combination/sequential therapies for anabolic and antiresorptive skelet al agents for osteoporosis. Curr Osteoporosis Rep 2006;4:5-13 (Pubitemid 44623942)
44. Boonen S, Marin F, Obermayer-Pietsch B, et al. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2008;93:852-60 (Pubitemid 351398563)
45. Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 2005;353:555-65 (Pubitemid 41138937)
46. Rittmaster RS, BologneseM, Ettinger MP, et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 2000;85:2129-34 (Pubitemid 32269232)
47. Eastell R, Nickelsen T, Marin F, et al. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European study of Forsteo (EUROFORS). J Bone Miner Res 2009; 24:726-36
48. Lyritis G, Marin F, Barker C, et al. Back pain during different sequential treatment regimens of teriparatide: results from EUROFORS. Curr Med Res Opin 2010;26:1799-807
49. Cosman F, Nieves J, Zion M, et al. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 2005;11:566-75 (Pubitemid 41138938)
50. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003;349:1207-15 (Pubitemid 37152030)
51. Neer R, Hayes A, Rao A, Finkelstein J. Effects of parathyroid hormone, alendronate or both on bone mineral density in osteoporotic postmenopausal women. J Bone Miner Res 2002;17S:135
52. Cosman F. Zoledronic acid (Reclast) and teriparatide (Forteo). ASBMR: Meeting highlights 2009;34:632-3
53. Cosman F, Nieves JW, Zion M, et al. Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate. J Bone Miner Res 2009;24:1110-15
54. Pleiner-Duxneuner J, Zwettler E, Paschalis E, et al. Treatment of osteoporosis with parathyroid hormone and teriparatide. Calcif Tissue Int 2009;84: 159-70
55. NICE 2008 Guideline TA087. The clinical effectiveness and cost effectiveness of technologies for the secondary prevention of osteoporotic fractures in postmenopausal women. Available at: http://guidance.nice.org.uk/ TA87 [Last accessed March 2011]
56. Compston J, Cooper A, Cooper C, et al. Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 2009;62:105-8
57. Body JJ, Bergmann P, Boonen S, et al. Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporos Int 2010;21:657-80
58. Miller PD, Delmas PD, Lindsay R, et al. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab 2008;93:3785-93
59. Chevalier Y, Quek E, Borah B, et al. Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body. Bone 2010;46:41-8
60. Lawson MA, Xia Z, Barnett BL, et al. Differences between bisphosphonates in binding affinities for hydroxyapatite. J Biomed Mater Res Part B Appl Biomater 2010;92:149-55